Nikkiso Co. Ltd. Announces Consolidated Earnings Results for Nine Months Ended September 30, 2017; Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2017; Provides Dividend Guidance for the Fiscal Year Ending December 31, 2017
November 13, 2017
Share
Nikkiso Co. Ltd. announced consolidated earnings results for nine months ended September 30, 2017. For the period, the company reported net sales of JPY 98,318 million compared to JPY 91,794 million a year ago. Operating income was JPY 1,167 million compared to JPY 3,398 million a year ago. Ordinary income was JPY 826 million compared to JPY 860 million a year ago. Profit attributable to owners of parent was JPY 1,128 million or JPY 14.01 per diluted share compared to JPY 255 million or JPY 3.04 per diluted share a year ago. Profit before income taxes was JPY 2,191 million compared to JPY 967 million a year ago.
The company provided consolidated earnings guidance for the fiscal year ending December 31, 2017. The company forecast net sales of JPY 140,000 million, operating income of JPY 4,000 million, ordinary income of JPY 3,700 million, net income of JPY 2,500 million or JPY 35.12 per share.
The company provided dividend guidance for the fiscal year ending December 31, 2017. The company expects year-end dividend of JPY 8 per share compared to JPY 8 per share paid a year ago.
NIKKISO CO.,LTD. is a Japan-based company principally engaged in the manufacture and sale of industrial pumps, precision equipment and blood related products, among others. The Company operates in two business segments. Industrial Business segment conducts industrial business including the manufacture, sale and maintenance of industrial special pumps, as well as liquefied gas & industrial gas related equipment and devices. The Segment is also involved in precision equipment business, aerospace business and deep ultraviolet light emitting diode (LED) business. Medical Business segmentâs products are dialysis-related products including hemodialysis and peritoneal dialysis, such as artificial dialysis machines, dialyzers, blood circuits, and powder-type dialysis agents. The Segment also manufactures, sells and maintains products and medicines related to CRRT (acute blood purification therapy), artificial pancreas devices that manage blood glucose, and energy devices for microwave surgery.
Nikkiso Co. Ltd. Announces Consolidated Earnings Results for Nine Months Ended September 30, 2017; Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2017; Provides Dividend Guidance for the Fiscal Year Ending December 31, 2017
NIKKISO CO., LTD. 